News

Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Modern Healthcare1d
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...
Pharmaceutical Technology on MSN10d
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.
Is Eli Lilly Stock a Buy?
Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...
New York Post7d
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...
Eli Lilly finds its weight-loss pill works just as well as Ozempic — and investors are loving it
Eli Lilly shares are now positive for the year, up 10% since the start of January.
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...